Aspen Pharmaceutical Holdings Ltd., GlaxoSmithKline sales and marketing update

GlaxoSmithKline will divest non-core consumer healthcare OTC products outside the U.S., Canada and Europe to Aspen for £164 million ($263.8 million) in cash. ...